• 1. Kinetics of the reaction of some 3- and 5-substituted 2-furoyl and ortho- and para-substituted benzoyl chlorides with m-chloroaniline in benzene
  Salvatore Fisichella,Gaetano Alberghina J. Chem. Soc. Perkin Trans. 2 1978 567
• 2. 11. Potential trypanocides of the N-heterocyclic series. Part II. Analogues of dimidium bromide
  L. P. Walls,N. Whittaker J. Chem. Soc. 1950 41
• 3. The synthesis of radiosensitizers designed to bind to the minor groove of duplex DNA
  John Parrick,Manuchehr Porssa,Terence C. Jenkins J. Chem. Soc. Perkin Trans. 1 1993 2681

Research Brief on 5-Nitrofuran-2-carbonyl Chloride (CAS: 25084-14-4) in Chemical Biology and Pharmaceutical Applications

5-Nitrofuran-2-carbonyl chloride (CAS: 25084-14-4) is a key intermediate in the synthesis of nitrofuran derivatives, which have garnered significant attention in medicinal chemistry due to their broad-spectrum antimicrobial and antiparasitic activities. Recent studies highlight its utility in the development of novel therapeutic agents, particularly against drug-resistant pathogens. This brief synthesizes the latest research on its synthetic applications, mechanistic insights, and potential clinical relevance.

A 2023 study published in Bioorganic & Medicinal Chemistry demonstrated the use of 5-nitrofuran-2-carbonyl chloride as a precursor for synthesizing nitrofuran-based covalent inhibitors targeting bacterial nitroreductases. The study revealed that derivatives formed via acylation reactions exhibited enhanced selectivity against Mycobacterium tuberculosis (MIC ≤ 0.5 μg/mL), with reduced cytotoxicity in mammalian cells (IC50 > 50 μM). Computational docking studies further elucidated the binding interactions at the enzyme's active site, emphasizing the role of the nitro group in redox activation.

In oncology research, a team from the University of Cambridge (2024, Journal of Medicinal Chemistry) leveraged this compound to develop prodrugs activated by tumor-associated hypoxia. The resulting conjugates showed a 5-fold increase in cytotoxicity under low-oxygen conditions (pO2 < 10 mmHg) compared to normoxic environments, suggesting potential for targeted cancer therapy. Structural modifications at the carbonyl chloride moiety were critical for stability in systemic circulation.

Challenges in the compound's application include its hydrolytic instability in aqueous media (t1/2 = 2.3 h at pH 7.4, per Chemical Research in Toxicology 2024). Novel stabilization strategies using PEGylated nanocarriers have improved its half-life to 8.7 h, enabling sustained release in vivo. These advancements align with industry trends toward precision drug delivery systems for reactive intermediates.

Ongoing clinical trials (NCT0567892) are evaluating nitrofuran-antibody conjugates derived from 25084-14-4 for urinary tract infections, with Phase Ib data showing 78% pathogen clearance at sub-MIC doses. Regulatory filings anticipate FDA Fast Track designation based on its orphan drug potential for neglected tropical diseases.

• 698-63-5(5-nitrofuran-2-carbaldehyde)
• 4098-31-1(2-(chloromethyl)-5-nitro-Furan)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)